Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries

Scotland has introduced a number of initiatives to enhance the prescribing of low-cost generic drugs versus originators and patent products in a class where these are seen as similar. The objective of this review is to appraise the influence of the various measures on subsequent utilization patterns...

Full description

Saved in:
Bibliographic Details
Published in:Expert review of pharmacoeconomics & outcomes research 2013-08, Vol.13 (4), p.469-482
Main Authors: Godman, Brian, Bishop, Iain, Finlayson, Alexander E, Campbell, Stephen, Kwon, Hye-Young, Bennie, Marion
Format: Article
Language:English
Subjects:
ACEIs
Ambulatory care
Analysis
Antidepressants
Antipsychotics
ARBs
atypical antipsychotics
clopidogrel
demand-side measures
Drug dosages
Expenditures
Generic drugs
generics
Health insurance
Manufacturers
Medical economics
Patients
Pharmaceuticals
Pharmacists
PPIs
Prescription drugs
Prescription writing
Prices and rates
Psychotropic drugs
Scotland
statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Scotland has introduced a number of initiatives to enhance the prescribing of low-cost generic drugs versus originators and patent products in a class where these are seen as similar. The objective of this review is to appraise the influence of the various measures on subsequent utilization patterns and expenditure in high-volume classes to provide guidance. This review is principally a narrative review of published studies. The authors' found supply-side measures resulted in generic prices as low as 3% of pre-patent loss prices. Multiple demand-side measures resulted in high international non-proprietary name prescribing, and a considerable increase in prescribing efficiency for the proton pump inhibitors, statins, renin-angiotensin inhibitor drugs and selective serotonin reuptake inhibitors. There were no specific activities encouraging the prescription of losartan versus other angiotensin receptor blockers or risperidone versus other atypical antipsychotic drugs following generics and no change in their utilization patterns post generics. The authors can conclude multiple measures are needed to change physician prescribing habits. Authorities cannot rely on any 'spillover' effects to affect future prescribing, even in closely related classes.
ISSN:1473-7167
1744-8379
DOI:10.1586/14737167.2013.820956